New Drug Functionally Cures 20% of Hepatitis B Patients

For the first time in decades, people living with chronic hepatitis B have real hope for a cure.

A new drug called bepirovirsen has functionally cured 20% of patients with chronic hepatitis B within just 48 weeks, according to clinical trials published in the New England Journal of Medicine. A functional cure means the virus becomes undetectable and patients can safely stop taking medication.

The results come from two major clinical trials involving more than 1,800 people across 29 countries, conducted by pharmaceutical companies Ionis Pharmaceuticals and GlaxoSmithKline. The FDA is expected to respond to the drug approval application in October.

"It's the first major advance in the treatment of chronic hepatitis B in decades," said Dr. William Jarnagin, a liver specialist at Memorial Sloan Kettering Cancer Center.

Hepatitis B is often called a "silent killer" because many people show no symptoms, yet the chronic form can lead to liver failure and death. The virus spreads through bodily fluids and from mothers to babies during birth.

About 240 million people worldwide live with chronic hepatitis B, with 1.2 million new infections every year. In the United States alone, roughly 640,000 people have the chronic form of the disease.

Until now, treatment has focused on managing the virus with antiviral medications and monitoring for complications like liver cancer. Current treatments help prevent the virus from replicating but cannot eliminate it completely or stop all cancer risks.

The Ripple Effect

This breakthrough could transform lives for hundreds of thousands of Americans and millions worldwide who have lived without hope of clearing the virus from their bodies. Beyond the 20% who achieved a functional cure, researchers are continuing to study how the drug works and how to improve its effectiveness for even more patients.

The development also highlights the power of modern medicine to tackle diseases once thought incurable. While a safe and effective vaccine has prevented countless infections since pediatricians began recommending it for all newborns, those already living with chronic hepatitis B have had limited options until now.

For people who have spent years managing a potentially deadly chronic illness, the possibility of becoming virus-free represents not just medical progress but genuine freedom.

One in five chronic hepatitis B patients now has a path to a cure that didn't exist before.